Trans Genic Group
2342.TServices
Filed as TRANS GENIC INC. (2022-06–2024-06)
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥274m | ¥287m | ¥371m | ¥397m | ¥365m | ¥377m |
| Operating income | ¥2m | −¥20m | ¥73m | ¥85m | ¥78m | −¥69m |
| Ordinary income | −¥22m | −¥37m | ¥87m | ¥73m | ¥76m | ¥32m |
| Total assets | ¥5.5bn | ¥6.4bn | ¥6.9bn | ¥8.0bn | ¥7.6bn | ¥4.7bn |
| Net assets / equity | ¥4.3bn | ¥4.7bn | ¥5.9bn | ¥6.7bn | ¥6.8bn | ¥4.4bn |
| EPS (basic) | ¥-29.06 | ¥-69.35 | ¥-39.41 | ¥-6.17 | ¥158.3 | ¥10.36 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 2
| Period | Form | Figures |
|---|---|---|
| 2024-04-01 → 2024-09-30 | Half-year | 71 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 200 figures · EDINET |
21 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| Drug Discovery Support Business | ¥2.3bn | −¥164m |
| Investments And Consulting Business | ¥10.9bn | ¥480m |
| Adjustments & eliminations | — | −¥177m |
| Total | ¥13.2bn | ¥315m |
Segment names from EDINET member IDs; not mapped to a common taxonomy.